出海创新仍为主线，港股创新药ETF(159567)跟踪指数趋势上行，康方生物、药明生物、亚盛医药-B领涨。

有连云06-24

2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，药明生物、亚盛医药-B跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到6194万元。平安证券表示，全球医药创新迎来新的大适应症时代，最近1-2年，在传统的肿瘤与自免等大病种之外，医药产业相继在减重、阿尔兹海默症、核医学等领域取得关键突破，行业蛋糕有望随之快速做大。国内医药创新支持政策陆续出台，叠加...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2445048978?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-24 14:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2445048978","market":"hk","top_or_hot":-1,"title":"出海创新仍为主线，港股创新药ETF(159567)跟踪指数趋势上行，康方生物、药明生物、亚盛医药-B领涨。","media":"有连云","content":"<div>\n<p>2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，药明生物、亚盛医药-B跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到6194万元。平安证券表示，全球医药创新迎来新的大适应症时代，最近1-2年，在传统的肿瘤与自免等大病种之外，医药产业相继在减重、阿尔兹海默症、核医学等领域取得关键突破，行业蛋糕有望随之快速做大。国内医药创新支持政策陆续出台，叠加...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>出海创新仍为主线，港股创新药ETF(159567)跟踪指数趋势上行，康方生物、药明生物、亚盛医药-B领涨。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n出海创新仍为主线，港股创新药ETF(159567)跟踪指数趋势上行，康方生物、药明生物、亚盛医药-B领涨。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-24 14:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b><strong>有连云</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，药明生物、亚盛医药-B跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到6194万元。平安证券表示，全球医药创新迎来新的大适应症时代，最近1-2年，在传统的肿瘤与自免等大病种之外，医药产业相继在减重、阿尔兹海默症、核医学等领域取得关键突破，行业蛋糕有望随之快速做大。国内医药创新支持政策陆续出台，叠加...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320764599.SGD","symbol_name":"FTIF - Templeton China A Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b","article_id":"2445048978","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2445048978","pubTimestamp":1719211305,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，药明生物、亚盛医药-B跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额达到6194万元。国内医药创新支持政策陆续出台，叠加美债利率下行预期，创新产业链有望迎来估值修复。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","BK1589":"北水核心资产","LU0052750758.USD":"富兰克林中国基金A Acc","BK1515":"抗疫概念","BK1574":"生物医药B类股","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","02269":"药明生物","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","09939":"开拓药业-B","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1720050803.USD":"安联全方位中国股票基金","BK1521":"挪威政府全球养老基金持仓","BK1610":"ETF&股票定投概念","BK1161":"生物科技","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0823426480.USD":"法巴中国股票经典Dis","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","09926":"康方生物","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0051755006.USD":"摩根大通中国A (dist)","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","06855":"亚盛医药-B"},"translate_title":"Overseas innovation is still the main line. The Hong Kong stock innovative drug ETF (159567) tracks the upward trend of the index, led by Akeso Biologics, WuXi Biologics, and Ascentage Pharma-B.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1,"09926":1,"09939":1,"02269":1},"content_text":"2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，药明生物、亚盛医药-B跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到6194万元。平安证券表示，全球医药创新迎来新的大适应症时代，最近1-2年，在传统的肿瘤与自免等大病种之外，医药产业相继在减重、阿尔兹海默症、核医学等领域取得关键突破，行业蛋糕有望随之快速做大。国内医药创新支持政策陆续出台，叠加美债利率下行预期，创新产业链有望迎来估值修复。海外市场相比国内具有更大的行业空间，而在欧美日等发达国家，当地市场往往还伴随着更高的人均健康消费支出水平，国内创新药企国际认可度不断提升，掘金海外市场大有可为。相关产品：港股创新药ETF（159567）本条资讯内容与数据仅供参考，不构成投资建议。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445048978"}